(Q38966960)

8 September 2017

title

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial (English)

1 reference

8 September 2017

1 reference

1 reference

William Jeffery Sandborn

13

object named as

William J Sandborn

1 reference

8 September 2017

17

Brian G Feagan

1 reference

8 September 2017

7

Remo Panaccione

1 reference

8 September 2017

11

Geert D'Haens

1 reference

8 September 2017

5

Larry W Stitt

1 reference

8 September 2017

10

Séverine Vermeire

1 reference

8 September 2017

Margaret K Vandervoort

15

object named as

Margaret K Vandervoort

1 reference

8 September 2017

14

Allan Donner

1 reference

8 September 2017

1

Reena Khanna

1 reference

8 September 2017

3

Barrett G Levesque

1 reference

8 September 2017

4

Guangyong Zou

1 reference

8 September 2017

8

Alain Bitton

1 reference

8 September 2017

16

Joan C Morris

1 reference

8 September 2017

2

Brian Bressler

1 reference

8 September 2017

Gordon R Greenberg

6

1 reference

8 September 2017

Pierre Paré

9

1 reference

8 September 2017

Donald MacIntosh

12

1 reference

8 September 2017

REACT Study Investigators

18

1 reference

8 September 2017

language of work or name

English

0 references

publication date

2 September 2015

1 reference

8 September 2017

1 reference

8 September 2017

volume

386

1 reference

8 September 2017

issue

10006

1 reference

8 September 2017

page(s)

1825-1834

1 reference

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestiv

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Gastroenterologists' prescribing of infliximab for Crohn's disease: a national survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn's disease: a US national practice survey comparing experts and non-experts.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Treatment allocation by minimisation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

A simple index of Crohn's-disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

EuroQol: the current state of play

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Validation of the EuroQol questionnaire in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Top-down or step-up treatment in Crohn's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Annual cost of care for Crohn's disease: a payor perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

The cost of hospitalization in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Cost effectiveness of treatments for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

How expensive is inflammatory bowel disease? A critical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900068-9

7 January 2021

10.1016/S0140-6736(15)00068-9

Identifiers

DOI

1 reference

8 September 2017

1 reference